Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Pathologic Complete Response (pCR) Rate and Predictors of Response to Taxane, Trastuzumab, and Pertuzumab in HER2‑Positive Breast Cancer: Secondary Analyses of EA1181/CompassHER2 pCR.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: August 20, 2026
TRADE: tolerability of adjuvant abemaciclib at 6 months after initial dose escalation in patients with early-stage HR-positive/HER2-negative breast cancer.
Journal: ESMO open
Published: April 10, 2026
TRADE: a phase II trial to assess the tolerability of abemaciclib dose escalation in early-stage HR-positive/HER2-negative breast cancer.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: August 21, 2025
Expression and function of ABCG2 and XIAP in glioblastomas.
Journal: Journal of neuro-oncology
Published: September 30, 2016
Use and Yield of Baseline Imaging and Laboratory Testing in Stage II Breast Cancer.
Journal: The oncologist
Published: April 14, 2016
Targeted BMI1 inhibition impairs tumor growth in lung adenocarcinomas with low CEBPα expression.
Journal: Science translational medicine
Published: October 09, 2015
Frequency of mutations in individuals with breast cancer referred for BRCA1 and BRCA2 testing using next-generation sequencing with a 25-gene panel.
Journal: Cancer
Published: April 18, 2014
Safety and outcome of patients treated with a modified outpatient intraperitoneal regimen for epithelial ovarian, primary peritoneal or fallopian tube cancer.
Journal: Chemotherapy
Published: July 23, 2013
Showing 1-9 of 9
Last Updated: 09/26/2026